Biopharma firms tap new legal and compliance leads. Five companies name new legal and compliance leaders to guide growth and strategy. Lisa Henderson, VP, Editorial, Informa Life Sciences November 10, 2026 BPGbio, a clinical-stage biopharmaceutical company advancing mitochondrial-targeted therapeutics, announced the appointment of Jason Krause at its senior vice president and general counsel. He will lead the company's legal and compliance, and IP operations, providing strategic counsel as it advances its clinical development programs across oncology and rare diseases. Krause previously served as outside counsel to BPGbio and its largest shareholder for the past four years. Most recently, he was M&A counsel at Foundation Building Materials and a corporate partner at Kirkland & Ellis LLP. His earlier career was spent as an attorney with Goodwin and White & Case. He has a JD from Columbia Law School and a BS from Brigham Young University. Caldera Therapeutics has named Lee Giguere, JD, to the position of chief legal officer. Giguere joins the company with more than 20 years of experience, bringing that to bear as the company prepares to become a publicly traded company and advance its IBD program into Phase II. He was most recently chief legal officer of enGene Therapeutics and, before that, Obsidian Therapeutics. He was also vice president and general counsel of Chiasma, deputy general counsel at Karyopharm Therapeutics, and senior securities and governance counsel at Boston Scientific. He began his career practicing business law at Goodwin Procter. He earned a JD from Northeastern University School of Law and a BS in finance from Northeastern University. Maria Ostrovsky joins Candel Therapeutics as its general counsel, bringing over 20 years of legal experience overseeing the company's legal, compliance, and corporate governance functions. Ostrovsky most recently served as senior vice president, general counsel, and chief compliance officer at Deciphera Pharmaceuticals, where she led the global legal and compliance function and built the company's healthcare compliance program. Ostrovsky also held legal and compliance roles at TESARO and at Takeda Oncology. Earlier in her career, she was a litigation associate at Cooley LLP and Cleary Gottlieb Steen & Hamilton LLP. Ostrovsky earned a JD from the University of Pennsylvania Law School and a BA from Middlebury College. Brian Savage was appointed president and chief legal officer of Lupin. Savage will lead the company's global Legal, Compliance and Intellectual Property Management Group functions and will be based in New Jersey. Savage joins Lupin from Teva Pharmaceuticals, where he held several senior leadership roles since 2015. Most recently, he served as Teva's executive vice president and interim global chief legal officer. Before joining Teva, Savage practiced law at Dechert LLP. He holds a JD from Yale Law School and a BA, summa cum laude, from the University of Pennsylvania. Novartis Brasil has appointed Ana Paula Neves as its ethics, risk, and compliance country head. Neves brings nearly three decades of experience, having held senior leadership responsibilities across Latin America and global pharmaceutical businesses. She most recently served as head of global ethics and compliance strategic projects Takeda, where she held roles of increasing authority. She also held leadership roles at Sanofi and began her pharmaceutical career at Merck, building experience in clinical trial management and research operations. She holds relevant certifications in compliance, healthcare compliance, and pharma marketing and a Bachelor of Pharmacy from the University of Sao Paulo. These announcements are from October 13 through November 10, 2026, as posted on BusinessWire, PRNewswire, GlobeNewswire, Yahoo Finance, SEC filings, or company websites. If posted prior to these dates, this will be noted in the summary. If your company has an executive appointment announcement related to compliance, legal, ethics, or governance, please forward to Brandy Fidler at [email protected]. Apr 27, 2027 TO Apr 29, 2027 Gaylord National Resort & Convention Center | Oxon Hill, MD Your complete guide to mitigate risk: Stay on the pulse of enforcement trends, supercharge your best practice playbook and expand your network at PCC 2026. VP, Editorial, Informa Life Sciences Lisa Henderson has over 20 years of experience covering the biopharma drug development industry, from clinical trials to commercialization. She began her B2B publishing career in information technology, college recruitment, and managed care before transitioning to biopharma through CenterWatch, a pioneering media company founded by Ken Getz that focused on the clinical trials enterprise. As Editor-in-Chief of Applied Clinical Trials, Lisa expanded her role to Editorial Director of Pharmaceutical Executive and Pharmaceutical Commerce, driving the shift from legacy publishing to digital-first media. At Informa Life Sciences, she leads media strategy and content for BioXconomy and Bioprocess International, aligning the division's media platforms, events, and audiences under a unified thought-leadership framework. Spotlight. Sponsored Content More on this topic. Nov 10, 2026 Nov 4, 2026 From Partnering and Investment insights to Scientific developments to Commercialization strategies, sign up to receive free to your mailbox

Novartis retains first place in 2026 Access to Medicine Index. 10 November 2026 Swiss pharma giant Novartis (NOVN: VX) today announced the company has ranked first place in the 2026 Access to Medicine Index. Published every two years, the Index is an independent assessment of how major research-based pharmaceutical companies are improving access to medicines. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 11 February 2026 2 April 1995 Company news directory. Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 10 November 2026 Company spotlight. A global immunology company commercializing efgartigimod, the first approved FcRn blocker, across multiple severe autoimmune diseases, and now buying Unnatural Products to add oral and long-acting peptide medicines. More features in pharmaceutical. 10 November 2026

Decoding Evommune's Q4 roadshow: molecular glues and market survival. PALO ALTO, Calif. - November 09, 2026 - In the high-stakes ecosystem of clinical-stage biotechnology, a concentrated flurry of late-year investor presentations rarely happens by accident. When a company packs its executive calendar with back-to-back appearances at premier institutional banking conferences, it usually signals one of two things: a victory lap following blockbuster clinical data, or a strategic campaign to control the narrative ahead of a critical financial maneuver. For Evommune, Inc. (NYSE: EVMN), which just announced a three-stop institutional roadshow spanning November and December, the reality appears to be a complex blend of both. The Palo Alto-based company is slated to present at the Stifel Healthcare Conference in New York on November 11, the Jefferies Global Healthcare Conference in London on November 18, and the Evercore Healthcare Conference in Coral Gables on December 2. But beyond the standard corporate slide decks and webcast links, this transatlantic tour represents a pivotal moment for a micro-cap biotech attempting to redefine the boundaries of chronic inflammatory disease treatment. As the company prepares to face the scrutiny of portfolio managers and sell-side analysts, the underlying story is a fascinating case study in how modern drug developers must balance cutting-edge molecular science with the unforgiving physics of capital markets. The financial chess board: cash, placements, and runways. To understand the urgency and timing of Evommune's conference blitz, one must look at the financial transactions that occurred just days before the roadshow was announced. On November 4, the company executed a highly strategic, two-pronged maneuver. First, it secured a $30 million private placement from specialist institutional investors. Concurrently, it announced the in-licensing of EVO570 - a promising preclinical asset - from Hinova Pharmaceuticals, paying $20 million in cash and issuing $10 million in warrants. The math here is revealing. While the $30 million infusion bolsters the balance sheet, the immediate $20 million cash outlay for the new asset leaves a net cash inflow of just $10 million from the transaction. For a clinical-stage company with an EBITDA hovering around negative $100 million, capital is oxygen, and runway is everything. "When a biotech company hits the road immediately following a private placement and an acquisition, management is essentially taking their new prize asset on a tour to justify the expenditure," noted one healthcare equity strategist familiar with the immunology space. "They need to convince the broader institutional market that this newly acquired mechanism of action is the key to unlocking future value, especially when the stock has been trading near the bottom of its 52-week range." Indeed, Evommune's stock has recently languished near its 52-week low of $4.94, a stark contrast to its all-time high of $33.20. By stepping into the spotlight at Stifel, Jefferies, and Evercore, management is actively working to reset the valuation narrative. The roadshow is less about presenting past earnings and entirely about selling the future - specifically, a future where Evommune's pipeline disrupts a multibillion-dollar immunology market currently dominated by aging blockbusters and therapies fraught with side effects. The "holy grail" of immunology: efficacy without the baggage. The centerpiece of Evommune's pitch to Wall Street will undoubtedly be EVO570, the newly acquired oral VAV1 molecular glue degrader. To understand why investors might care about this specific protein, one must look at the current landscape of autoimmune therapies and the inherent limitations of standard treatments. For years, Janus kinase (JAK) inhibitors like Xeljanz and Rinvoq have been highly effective in treating conditions ranging from rheumatoid arthritis to atopic dermatitis. However, these drugs act as broad immunosuppressants and carry FDA black-box warnings for serious infections, cardiovascular events, and malignancies. The "holy grail" for immunologists and biotech investors alike is a therapy that delivers JAK-like efficacy without the associated systemic liabilities. Evommune believes EVO570 is exactly that. VAV1 is a protein found almost exclusively in immune cells, meaning a drug that degrades it could theoretically halt rogue immune responses without causing collateral damage to other bodily systems. The concept of molecular glue degraders - therapeutics that hijack the body's natural disposal system to eliminate disease-causing proteins - is currently one of the hottest areas in biotechnology. While pharmaceutical giant Novartis is developing its own VAV1 degrader (MRT-6160), Evommune's management is expected to use these conferences to assert that EVO570 is up to 20 times more potent. The upcoming fireside chats will likely feature aggressive questioning from analysts on whether this in vitro potency will translate into superior human clinical data when Phase 1 trials begin in mid-2027. Validated pathways and the broader pipeline. While the molecular glue narrative offers a compelling hook, institutional investors generally prefer pipelines with multiple shots on goal. Evommune will use the roadshow to remind the market that it is not a single-asset company, showcasing a diversified approach to chronic inflammation. Management is expected to highlight EVO646, an oral TLR7/8 antagonist slated to enter the clinic in the first half of 2027. This candidate represents a masterclass in strategic drug design, targeting innate immunity and autoantibodies by blocking type 1 interferon production and reducing B-cell activation. For analysts, this is a highly attractive proposition because the biological pathways are already validated in the real world. Anifrolumab (Saphnelo) validated the interferon pathway in lupus, while belimumab (Benlysta) validated the B-cell pathway. By combining these mechanisms into a single oral therapy, Evommune is positioning EVO646 as a potential paradigm shift for systemic lupus erythematosus and myasthenia gravis. Furthermore, the company recently presented late-breaking Phase 2a proof-of-concept data for EVO301 in Atopic Dermatitis at the European Academy of Dermatology and Venereology Congress in October. While the atopic dermatitis market is fiercely competitive - dominated by Sanofi and Regeneron's Dupixent and a host of topical treatments - any oral therapy showing strong efficacy and safety signals commands immediate market attention. Investors at the Stifel and Jefferies conferences will likely press management for granular details on this Phase 2a data, seeking clarity on how EVO301 can carve out market share against entrenched competitors. The verdict of the institutional jury. As Evommune embarks on this critical investor tour, the stakes are undeniably high. The transition from preclinical promise to clinical reality is the most treacherous phase of a biotechnology company's lifecycle. The science must be flawless, but the storytelling must be equally compelling to keep the capital flowing. Portfolio managers sitting in the audience in New York, London, and Coral Gables will be listening for specific cues. They want to know the precise timeline for the EVO570 and EVO646 clinical readouts. They will be calculating the company's cash burn rate against its current reserves, attempting to predict when the next dilutive financing event might occur. Most importantly, they will be assessing the management team's ability to navigate a therapeutic landscape where the margins between a blockbuster drug and a clinical failure are razor-thin. In the end, Evommune's Q4 roadshow is a microcosm of the broader biotechnology industry. It is a space where human ingenuity attempts to outsmart complex biological systems, funded by capital markets that demand both visionary innovation and strict financial discipline. Whether Evommune can successfully thread this needle remains to be seen, but over the next month, the institutional jury will be listening closely to their opening arguments. Topics & related. Biotechnology Drug Development Industry Conference Private Placement Pharmaceuticals & Therapeutics Stock Price Are you a relevant expert who could contribute your opinion or insights to this article? BriefGlance'd love to hear from you. BriefGlance will give you full credit for your contribution. UAID: 54300